MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova has published a secondary analysis of a Phase 2 trial for MN-166 (ibudilast) in treating alcohol use disorder (AUD) in Alcoholism: Clinical and Experimental Research. The study involved 52 participants and revealed that MN-166 significantly reduced heavy drinking rates and cravings. The analysis showed it didn't alter stimulation/sedation levels but moderated daily stimulation effects on alcohol consumption. With an estimated 14.5 million people affected by AUD in the U.S., the study highlights a critical need for better treatment options.
MediciNova, a biopharmaceutical company traded as NASDAQ:MNOV, announced a Notice of Allowance from the Korean Intellectual Property Office for patents covering MN-001 (tipelukast) and its metabolite MN-002, aimed at treating advanced nonalcoholic steatohepatitis (NASH). The patent is expected to expire no earlier than May 2035 and covers multiple aspects of treatment, including dosing forms and frequencies. Positive results from a prior Phase 2 clinical trial of MN-001 with NASH patients alongside FDA's Fast Track designation further highlight its potential.
MediciNova, Inc. (NASDAQ: MNOV) has announced that Geoffrey O'Brien, the Vice President and Executive Officer, will present at the 2022 Virtual Growth Conference, scheduled for March 28-30, 2022. MediciNova is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is in Phase 3 trials for ALS and DCM, while MN-001 (tipelukast) is preparing for a Phase 2 trial in NASH. MediciNova has a strong pipeline with 11 programs currently in clinical development.
MediciNova, Inc. announced that MN-166 (ibudilast) is highlighted in the Global Spine Journal as a potential treatment for degenerative cervical myelopathy (DCM). The publication reviews therapies that support neuroprotection, neuroregeneration, and neuromodulation. MN-166 is noted for its anti-inflammatory and neuroprotective effects, making it the only drug currently in Phase 3 trials for DCM. Chief Medical Officer Kazuko Matsuda expressed optimism regarding MN-166's potential to aid patients with DCM, a condition that often leads to lifelong disability.
MediciNova (NASDAQ: MNOV) announced that MN-166 (ibudilast) is recognized as a promising treatment for alcohol use disorder (AUD) in a journal publication. The article, co-authored with Dr. Lara Ray, outlines that MN-166 is effective in reducing alcohol intake and cravings, improving mood, and mitigating the effects of alcohol. With 14.5 million individuals in the U.S. suffering from AUD, and only a small percentage receiving treatment, MN-166's potential could address this significant medical need. The drug is in late-stage development for multiple conditions.
MediciNova, a biopharmaceutical company, announced it received a new patent from the Korean Intellectual Property Office for MN-001 (tipelukast) aimed at treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. The patent is expected to expire no earlier than July 2034 and covers various dosages and administration forms. The company notes promising results from its Phase 2 trial with MN-001, showing a significant reduction in serum triglycerides. MediciNova continues to develop innovative therapies for various diseases.
MediciNova, Inc. (NASDAQ: MNOV) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent concerning MN-001 (tipelukast) and its metabolite MN-002, which target hepatic ballooning. This patent is anticipated to be granted by January 2035 and covers various oral administration forms. The Chief Medical Officer highlighted MN-001's efficacy in improving NASH pathology in animal models. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, currently advancing multiple clinical programs, including MN-166 for ALS.
MediciNova, a biopharmaceutical company trading as MNOV, announced receiving a Notice of Intention to Grant from the European Patent Office for MN-166 (ibudilast), targeting alcohol use disorder (AUD). This patent, expected to expire no earlier than May 2037, covers various dosage regimens and combination therapies. Clinical trials have shown MN-166 significantly reduces heavy drinking and alcohol cravings. The company aims to meet the high unmet medical need for AUD treatments, with ongoing studies funded by the NIH and collaborations with UCLA.
MediciNova, Inc. announced receiving a Notice of Intention to Grant from the European Patent Office for MN-001 (tipelukast) and MN-002 related to inhibiting hepatic ballooning, with expected patent expiration in January 2035. The claims cover oral forms and various dosages. MN-001 has shown promising results in improving NASH pathology in animal models, with significant NAFLD activity score improvements. The company is focused on developing therapies for fibrotic and neurodegenerative diseases, with MN-166 also in late-stage trials for ALS and MS.
MediciNova, traded as MNOV on NASDAQ, announced a Notice of Allowance from the U.S. Patent Office for a patent covering the combination of MN-166 (ibudilast) and riluzole for treating amyotrophic lateral sclerosis (ALS). This patent is expected to expire no earlier than November 2035 and includes various dosage forms. Chief Medical Officer Kazuko Matsuda stated that this patent will enhance the company's ALS patent portfolio. ALS affects approximately 16,000 patients in the U.S. annually, highlighting the potential market for MN-166.